Brought to you by 
GSK buys some AstraZeneca OTC products for $253mm
02 Dec 2022
Executive Summary
AstraZeneca has sold a group of its OTC drugs to GlaxoSmithKline Consumer Healthcare for $253mm in cash, getting more than five times what the portfolio achieved in 2007 sales. AZ's AZ Tika division currently markets these products.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK buys some AstraZeneca OTC products for $253mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice